Optimizing the formulation of procationic liposomes-protamine-DNA complexes by response surface methodology.
Zhi-Rong Zhong1, Zhong-Bing Liu, Li Tu
1West China School of Pharmacy, Sichuan University, Chengdu 610041, Sichuan, PR China.
PDA Journal of Pharmaceutical Science and Technology
|October 16, 2007
Summary
Researchers optimized procationic liposomes-protamine-DNA (PLPD) gene delivery vectors using response surface methodology. The optimized formulation achieved a particle size of 228.9 nm and transfectivity of 24.26 mU/mg, demonstrating effective gene delivery potential.
Area of Science:
- Biotechnology
- Gene Delivery Systems
- Nanomedicine
Background:
- Non-viral gene delivery vectors are crucial for therapeutic applications.
- Procationic liposomes-protamine-DNA (PLPD) offer a promising non-viral gene delivery approach.
- Optimization of PLPD formulation is essential for maximizing efficacy.
Purpose of the Study:
- To optimize the formulation of procationic liposomes-protamine-DNA (PLPD) gene delivery vectors.
- To identify optimal parameters for PLPD particle size and transfectivity.
- To utilize response surface methodology (RSM) for efficient formulation optimization.
Main Methods:
- Response surface methodology (RSM) with a three-factor, five-level design was employed.
- Independent variables included protamine/DNA ratio, CHETA molar percent, and CHETA/DNA ratio.
- PLPD particle size and beta-galactosidase activity (transfectivity) were measured as response variables.
Main Results:
- Mathematical models and response surface plots were generated to correlate variables.
- Optimized levels of independent variables were predicted to achieve desired particle size and transfectivity.
- The optimized PLPD formulation exhibited a particle size of 228.9 ± 8.0 nm and transfectivity of 24.26 ± 2.60 mU/mg.
Conclusions:
- RSM effectively optimized PLPD formulation for enhanced gene delivery.
- The optimized PLPD vectors demonstrate favorable particle size and high transfectivity.
- This study provides a robust method for developing efficient non-viral gene delivery systems.


